DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70271 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Arnon Haran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Mutation, Proto-Oncogene Proteins, Hemorrhage. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Introduction
Thrombosis and bleeding events are major causes of morbidity and mortality in patients with myeloproliferative neoplasms (MPN). The contribution of non‐driver mutations, in particular mutations in DNMT3A , TET2, and ASXL1 (collectively DTA) to thrombo‐hemorrhagic risk remains unclear.
Methods
We conducted a retrospective analysis of 180 patients with MPN undergoing next generation sequencing to evaluate the association between DTA mutations and major bleeding and thrombotic events occurring from 3 years prior to diagnosis through follow‐up. Patients were stratified by disease subtype, and Cox proportional hazards models were used for univariate and multivariate analyses.
Results
DTA mutations were present in 40% of the patients. 52 (29%) patients suffered from arterial or venous thrombotic events either following diagnosis or as early as 3 years prior to diagnosis, and 20 (11%) experienced major bleeding events during the same period. In patients with PV and ET, DNMT3A and TET2 (DT) mutations were significantly associated with venous thrombosis (HR 5.6, 95% CI 1.6–19.1) and were also associated with major bleeding in univariate analyses (HR 6.7, 95% CI 1.7–26.9). The association with venous thrombosis remained significant after multivariable adjustment, whereas the association with major bleeding was attenuated after adjustment for age and smoking status (HR 4.1, 95% CI 0.9–19.2). No such associations were observed in patients with myelofibrosis.
Conclusion
Our findings highlight an association between DT mutations and thrombotic and bleeding complications in patients with PV and ET and support further evaluation of molecular markers as contributors to thrombo‐hemorrhagic risk in MPN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
- Faculty of Medicine, Hebrew University of Jerusalem, Israel.
ORCID-Profile: Arnon Haran, Ela Shai, Batia Roth, Eran Zimran
Zitieren
APA
Haran, A., Wasserstrom, A., Vainstein, V., Kazoom, R., Shai, E., Arad, A., Roth, B., Buchman, N., Kalish, Y., & Zimran, E. (2026). DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia. European Journal of Haematology. https://doi.org/10.1111/ejh.70271
Vancouver
Haran A, Wasserstrom A, Vainstein V, Kazoom R, Shai E, Arad A, et al. DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia. European Journal of Haematology. 2026. doi:10.1111/ejh.70271
BibTeX
@article{Haran2026,
author = {Haran, Arnon and Wasserstrom, Avital and Vainstein, Vladimir and Kazoom, Romi and Shai, Ela and Arad, Ariela and Roth, Batia and Buchman, Noa and Kalish, Yosef and Zimran, Eran},
title = {DNMT3A and TET2 Mutations are Associated With Both Venous Thrombosis and Major Bleeding in Patients With Polycythemia Vera and Essential Thrombocythemia},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70271}
}
EUVIMED